EU approves Gilenya for paediatric MS
European regulators have approved Novartis’ Gilenya for the treatment of children and adolescents from 10 to 17 years old with relapsing-remitting forms of multiple sclerosis (RRMS).
Read More
Tag: Gilenya
FDA approves Novartis’ Gilenya for paediatric use
US regulators have approved Novartis’ Gilenya to treat children and adolescents with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy indicated for this patient group.
Read More
Novartis’ Gilenya hits targets in paediatric MS trial
Novartis has released top-line data showing that Gilenya significantly reduced relapses in children and adolescents with multiple sclerosis.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
